Search

Your search keyword '"Tumors -- Drug therapy -- Genetic aspects"' showing total 40 results
Start Over Descriptor "Tumors -- Drug therapy -- Genetic aspects"
40 results on '"Tumors -- Drug therapy -- Genetic aspects"'

1. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Author

Dillon, Magnus T., Guevara, Jeane, Mohammed, Kabir, Patin, Emmanuel C., Smith, Simon A., Dean, Emma, Jones, Gemma N., Willis, Sophie E., Petrone, Marcella, Silva, Carlos, Thway, Khin, Bunce, Catey, Roxanis, Ioannis, Nenclares, Pablo, Wilkins, Anna, McLaughlin, Martin, Jayme-Laiche, Adoracion, Benafif, Sarah, Nintos, Georgios, Kwatra, Vineet, Grove, Lorna, Mansfield, David, Proszek, Paula, Martin, Philip, Moore, Luiza, Swales, Karen E., Banerji, Udai, Saunders, Mark P., Spicer, James, Forster, Martin D., and Harrington, Kevin J.

Subjects
Tumors -- Drug therapy -- Genetic aspects, Inflammation -- Drug therapy -- Genetic aspects, Health care industry
Abstract

BACKGROUND. Phase 1 study of ATR inhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced solid tumors. METHODS. The primary objective was safety. Secondary objectives included assessment of antitumor responses and pharmacokinetic (PK) and pharmacodynamic (PD) studies. Sixty-seven patients received 20-240 mg ceralasertib BD continuously or intermittently (14 of a 28-day cycle). RESULTS. Intermittent dosing was better tolerated than continuous, which was associated with dose-limiting hematological toxicity. The recommended phase 2 dose of ceralasertib was 160 mg twice daily for 2 weeks in a 4-weekly cycle. Modulation of target and increased DNA damage were identified in tumor and surrogate PD. There were 5 (8%) confirmed partial responses (PRs) (40-240 mg BD), 34 (52%) stable disease (SD), including 1 unconfirmed PR, and 27 (41%) progressive disease. Durable responses were seen in tumors with loss of AT-rich interactive domain-containing protein 1A (ARID1A) and DNA damageresponse defects. Treatment-modulated tumor and systemic immune markers and responding tumors were more immune inflamed than nonresponding. CONCLUSION. Ceralasertib monotherapy was tolerated at 160 mg BD intermittently and associated with antitumor activity. TRIAL REGISTRATION. Clinicaltrials.gov: NCT02223923, EudraCT: 2013-003994-84. FUNDING. Cancer Research UK, AstraZeneca, UK Department of Health (National Institute for Health Research), Rosetrees Trust, Experimental Cancer Medicine Centre., Introduction ATR (ataxia telangiectasia and Rad3-related) is a critical kinase in the DNA damage response (DDR) (1, 2). Preclinical data have identified multiple cancer-related phenotypes sensitizing tumor cells to monotherapy [...]

Published
2024
Full Text
View/download PDF

2. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade

Author

Ghosh, Arnab, Michels, Judith, Mezzadra, Riccardo, Venkatesh, Divya, Dong, Lauren, Gomez, Ricardo, Samaan, Fadi, Ho, Yu-Jui, Campesato, Luis Felipe, Mangarin, Levi, Fak, John, Suek, Nathan, Holland, Aliya, Liu, Cailian, Abu-Akeel, Mohsen, Bykov, Yonina, Zhong, Hong, Fitzgerald, Kelly, Budhu, Sadna, Chow, Andrew, Zappasodi, Roberta, Panageas, Katherine S., de Henau, Olivier, Ruscetti, Marcus, Lowe, Scott W., Merghoub, Taha, and Wolchok, Jedd D.

Subjects
Tumor proteins -- Genetic aspects -- Physiological aspects, Tumors -- Drug therapy -- Genetic aspects, Immune response -- Genetic aspects, Macrophages -- Genetic aspects -- Physiological aspects, Monoclonal antibodies -- Testing -- Genetic aspects, Health care industry
Abstract

In addition to playing a major role in tumor cell biology, p53 generates a microenvironment that promotes antitumor immune surveillance via tumor-associated macrophages. We examined whether increasing p53 signaling in the tumor microenvironment influences antitumor T cell immunity. Our findings indicate that increased p53 signaling induced either pharmacologically with APR-246 (eprenetapopt) or in p53-overexpressing transgenic mice can disinhibit antitumor T cell immunity and augment the efficacy of immune checkpoint blockade. We demonstrated that increased p53 expression in tumor-associated macrophages induces canonical p53-associated functions such as senescence and activation of a p53 dependent senescence-associated secretory phenotype. This was linked with decreased expression of proteins associated with M2 polarization by tumor-associated macrophages. Our preclinical data led to the development of a clinical trial in patients with solid tumors combining APR-246 with pembrolizumab. Biospecimens from select patients participating in this ongoing trial showed that there was a suppression of M2-polarized myeloid cells and increase in T cell proliferation with therapy in those who responded to the therapy. Our findings, based on both genetic and a small molecule-based pharmacological approach, suggest that increasing p53 expression in tumor-associated macrophages reprograms the tumor microenvironment to augment the response to immune checkpoint blockade., Introduction A major hurdle in the successful application of immunotherapies is poor infiltration of functional antitumor T cells in the immuno-suppressive tumor microenvironment (TME) (1, 2). Infiltrating myeloid cells that [...]

Published
2022
Full Text
View/download PDF

3. New Solid Cancer Data Have Been Reported by Researchers at University of Texas MD Anderson Cancer Center (A Phase Ii Study of Tas-117 In Patients With Advanced Solid Tumors Harboring Germline Pten-inactivating Mutations)

Subjects
Gene mutations -- Health aspects, Tumors -- Drug therapy -- Genetic aspects, Antineoplastic agents -- Testing, Phosphatases -- Genetic aspects, Antimitotic agents -- Testing, Health
Abstract

2022 OCT 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Oncology - Solid Cancer. According to news [...]

Published
2022

4. Institute Bergonie Researcher Updates Understanding of Solid Cancer [Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM)]

Subjects
Oncology, Experimental, Gene mutations -- Research, Tumors -- Drug therapy -- Genetic aspects, Drug resistance -- Research, Extrachromosomal DNA -- Health aspects, Cancer -- Research, Health
Abstract

2022 JUL 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on solid cancer are discussed in a new report. According [...]

Published
2022

5. Data on Solid Cancer Published by a Researcher at University of Ulsan College of Medicine [A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors]

Subjects
Tumors -- Drug therapy -- Genetic aspects, Antineoplastic agents -- Testing -- Dosage and administration, Proto-oncogenes -- Health aspects, Antimitotic agents -- Testing -- Dosage and administration, Health
Abstract

2022 JUL 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on solid cancer. According to news reporting from [...]

Published
2022

6. Yongchuan Hospital of Chongqing Medical University Researchers Provide New Insights into Lung Cancer (Weighted Gene Co-Expression Network Analysis and Treatment Strategies of Tumor Recurrence-Associated Hub Genes in Lung Adenocarcinoma)

Subjects
Oncology, Experimental -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Genetic research -- Genetic aspects, Adenocarcinoma -- Drug therapy -- Genetic aspects, Genes -- Genetic aspects, Diseases -- Relapse, Cancer -- Genetic aspects -- Research, Lung cancer -- Genetic aspects -- Drug therapy, Physical fitness, Health
Abstract

2021 DEC 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on lung cancer have been presented. According to news originating [...]

Published
2021

7. Senhwa Biosciences seeks US FDA and Health Canada approvals for CX-5461 to treat solid tumors with BRCA2 or PALB2 mutations

Subjects
United States. Food and Drug Administration, Cancer treatment, Talazoparib, Cancer research -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Senhwa Biosciences Inc, a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced that it has submitted multiple Investigational New Drug (IND) [...]

Published
2020

8. Researchers from University of Guelph Detail New Studies and Findings in the Area of Cancer Gene Therapy (De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors)

Subjects
Lung cancer -- Genetic aspects -- Drug therapy, Cancer genetics -- Genetic aspects -- Drug therapy, Genetic research -- Health aspects -- Genetic aspects, Gene therapy -- Health aspects, Monoclonal antibodies -- Genetic aspects -- Health aspects, Women's health -- Health aspects, Cancer research -- Health aspects -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, T cells -- Health aspects -- Genetic aspects, Health, Women's issues/gender studies
Abstract

2020 NOV 19 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in Biotechnology - Cancer Gene Therapy. According to news reporting [...]

Published
2020

9. Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors

Subjects
Genetic research -- Health aspects -- Genetic aspects, Cetuximab -- Health aspects, Cancer -- Genetic aspects -- Drug therapy, Women's health -- Health aspects, Genes -- Genetic aspects -- Health aspects, Afatinib -- Health aspects, Gene mutation -- Genetic aspects -- Health aspects, Tumors -- Drug therapy -- Genetic aspects, Colorectal cancer -- Genetic aspects -- Drug therapy, Pembrolizumab -- Health aspects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health, Women's issues/gender studies
Abstract

2020 NOV 12 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New results from early clinical trials of a drug that targets a cancer-causing mutation [...]

Published
2020

10. Reports on Acute Lymphoblastic Leukemia from Shinshu University School of Medicine Provide New Insights (PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by ...)

Subjects
Physical fitness, Cancer genetics -- Genetic aspects -- Drug therapy, Genetic research -- Genetic aspects, Methylation, Genes -- Genetic aspects, Transcription (Genetics) -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Acute lymphocytic leukemia -- Drug therapy -- Genetic aspects, Medical schools, RNA -- Genetic aspects, Health
Abstract

2020 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Oncology - Acute Lymphoblastic Leukemia. According to [...]

Published
2020

11. Reports from Seoul National University College of Medicine Advance Knowledge in Lung Cancer (Relationship of EGFR Mutation to Glucose Metabolic Activity and Asphericity of Metabolic Tumor Volume in Lung Adenocarcinoma)

Subjects
Viacom Media Networks, Lung cancer -- Genetic aspects -- Drug therapy, Cable television broadcasting industry, Adenocarcinoma -- Drug therapy -- Genetic aspects, Physical fitness, Glucose -- Genetic aspects, Glucose metabolism -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Medical schools, Health
Abstract

2020 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Oncology - Lung Cancer is the subject of a [...]

Published
2020

12. KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors

Subjects
Medical research, Medicine, Experimental, Tumors -- Drug therapy -- Genetic aspects, Cancer -- Genetic aspects, Clinical trials, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: KSQ THERAPEUTICS has issued the following news release: KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically [...]

Published
2021

13. KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors

Subjects
Medical research, Medicine, Experimental, Tumors -- Drug therapy -- Genetic aspects, Cancer -- Genetic aspects, Clinical trials, Business, Business, international
Abstract

CAMBRIDGE, Mass. -- KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically screen the whole genome in cancer [...]

Published
2021

14. NEW COMPUTATIONAL METHOD DETECTS DISRUPTED PATHWAYS IN CANCER METHOD WILL PROVIDE TUMOR BIOLOGISTS WITH THE DATA THEY NEED TO DEVELOP NEW CANCER TREATMENTS

Subjects
Gene mutations -- Analysis -- Genetic aspects -- Methods, Tumors -- Drug therapy -- Genetic aspects, Genetic research -- Methods -- Analysis -- Genetic aspects, News, opinion and commentary, University at Buffalo
Abstract

BUFFALO, N.Y. -- The following information was released by the University at Buffalo - SUNY: Cancer is a notoriously complex disease, in part because it may be caused by mutations [...]

Published
2021

15. Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Subjects
United States. Food and Drug Administration, Cancer treatment, Talazoparib, Cancer research -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, General interest, News, opinion and commentary
Abstract

TAIPEI: Senhwa Biosciences, Inc. has issued the following news release: Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment [...]

Published
2020

16. Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Subjects
United States. Food and Drug Administration, Cancer treatment, Talazoparib, Cancer research -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Business, international, Law
Abstract

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple Investigational [...]

Published
2020

17. Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Subjects
United States. Food and Drug Administration, Oncology, Experimental -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Cancer -- Care and treatment -- Research, Business, News, opinion and commentary
Abstract

TAIPEI and SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of [...]

Published
2020

18. PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Subjects
United States. Food and Drug Administration, Cancer treatment, Tumor proteins -- Genetic aspects -- Drug therapy, Tumors -- Drug therapy -- Genetic aspects, Cancer patients -- Drug therapy, Drug approval, Business, international, Law
Abstract

(GlobeNewswire) - PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced that the U.S. Food [...]

Published
2020

19. PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Subjects
United States. Food and Drug Administration, Cancer treatment, Tumor proteins -- Genetic aspects -- Drug therapy, Tumors -- Drug therapy -- Genetic aspects, Cancer patients -- Drug therapy, Drug approval, Banking, finance and accounting industries, Business
Abstract

CRANBURY, N.J., Oct 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting [...]

Published
2020

20. Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors

Subjects
United States. Food and Drug Administration, Chemotherapy, Tumors -- Drug therapy -- Genetic aspects, Business, international, Law
Abstract

(GlobeNewswire) - Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the Food and Drug Administration (FDA) granted [...]

Published
2020

21. Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors

Subjects
United States. Food and Drug Administration, Chemotherapy, Tumors -- Drug therapy -- Genetic aspects, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Aug 24, 2020 (GLOBE NEWSWIRE via COMTEX) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today [...]

Published
2020

22. Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation

Subjects
United States. Food and Drug Administration, Tumors -- Drug therapy -- Genetic aspects, Epidermal growth factors -- Genetic aspects, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, Jul 28, 2020 (GLOBE NEWSWIRE via COMTEX) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, [...]

Published
2020

23. Merck's Keytruda nabs 2nd biomarker-driven FDA nod, regardless of tumor type

Author

Liu, Angus

Subjects
Merck & Company Inc., Tumors -- Drug therapy -- Genetic aspects, Pharmaceutical industry, Drug approval, Pharmaceuticals and cosmetics industries, Opdivo (Medication), Keytruda (Medication)
Abstract

Byline: Angus Liu Three years ago, Merck & Co.'s Keytruda became the first drug to nab an FDA approval to treat any cancer bearing certain specific genetic features, regardless of [...]

Published
2020

24. Investigators at Weill Cornell Medicine Target Colon Cancer (Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair)

Subjects
Genetic research, Physical fitness, Cancer genetics -- Drug therapy -- Genetic aspects, Cancer prevention, Tumors -- Drug therapy -- Genetic aspects, DNA, Colorectal cancer -- Drug therapy -- Genetic aspects, Health
Abstract

2017 JUN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Oncology - Colon Cancer. According to news [...]

Published
2017

26. Researchers from Baylor University College of Medicine Report Findings in Leukemia (Small-molecule Inhibitor of Af9/enl-dot1l/af4/aff4 Interactions Suppresses Malignant Gene Expression and Tumor Growth)

Subjects
United States. National Institutes of Health -- Reports, Oncology, Experimental -- Reports -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Gene expression -- Genetic aspects -- Reports, Genetic research -- Genetic aspects -- Reports, Genes -- Reports -- Genetic aspects, Antineoplastic agents -- Reports, Cancer -- Prevention -- Genetic aspects -- Research, Antimitotic agents -- Reports, Health
Abstract

2021 AUG 27 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on Oncology - Leukemia are presented in a new report. According [...]

Published
2021

27. Studies in the Area of Obesity Reported from College of Medicine and Science (Unexpected Obesity, Rather Than Tumorigenesis, In a Conditional Mouse Model of Mitochondrial Complex Ii Deficiency)

Subjects
Obesity -- Genetic aspects -- Drug therapy, Tumors -- Drug therapy -- Genetic aspects, Medical colleges, Electron transport -- Genetic aspects, Health
Abstract

2021 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- Data detailed on Nutritional and Metabolic Diseases and Conditions - Obesity have been [...]

Published
2021

28. Researchers at IRCCS Regina Elena National Cancer Institute Have Reported New Data on Lung Cancer (KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden)

Subjects
Lung cancer -- Genetic aspects -- Drug therapy, Adenocarcinoma -- Drug therapy -- Genetic aspects, Cancer research -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Immunotherapy, Health
Abstract

2020 SEP 16 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Oncology - Lung Cancer. According to news originating from Rome, [...]

Published
2020

29. Researchers at Sapporo Medical University School of Medicine Report New Data on Colon Cancer (Upregulation of adipocyte enhancer-binding protein 1 in endothelial cells promotes tumor angiogenesis in colorectal cancer)

Subjects
Protein binding -- Genetic aspects -- Reports, Cancer research -- Reports -- Genetic aspects, Endothelium -- Genetic aspects -- Reports, Tumors -- Drug therapy -- Genetic aspects, RNA sequencing -- Reports -- Genetic aspects, Colorectal cancer -- Genetic aspects -- Drug therapy, Business, Health, Health care industry
Abstract

2020 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology - Colon Cancer have been published. According to news reporting [...]

Published
2020

30. Research from Institute for Cancer Research and Treatment (IRCCS) Broadens Understanding of Follicular Lymphoma

Subjects
Oncology, Experimental, Health, Tumors -- Drug therapy -- Genetic aspects, Lymphomas -- Drug therapy -- Genetic aspects, Cancer -- Care and treatment -- Research, Lymphatic diseases -- Drug therapy -- Genetic aspects, Health
Abstract

Researchers detail in 'In situ follicular lymphoma: pathologic characteristics and diagnostic features,' new data in Follicular Lymphoma. 'The diagnosis of in situ follicular lymphoma (FL) is feasible when immunohistochemical characterization [...]

Published
2012

32. GENETIC ACCOMPLICE HELPS SOME LUNG TUMORS EVADE TREATMENT

Subjects
Oncology, Experimental, Tumors -- Drug therapy -- Genetic aspects, Genetic research, Cancer -- Care and treatment -- Research, Lung cancer -- Drug therapy -- Genetic aspects, News, opinion and commentary
Abstract

CHEVY CHASE, MD -- The following information was released by the Howard Hughes Medical Institute (HHMI): For some patients with lung cancer, the drug erlotinib is a near miracle. Within [...]

Published
2011

34. AVEO's Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations

Subjects
Endothelial growth factors -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Lung tumors -- Drug therapy -- Genetic aspects, Cancer -- Care and treatment, Pharmaceutical industry -- Genetic aspects, Business, Business, international
Abstract

Preclinical Data Presented at International Lung Conference; Underscores Tivozanib Potency CAMBRIDGE, Mass. -- AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize [...]

Published
2009

35. Data from University of Miami Miller School of Medicine Provide New Insights into Leukemia

Subjects
Tumors -- Drug therapy -- Genetic aspects, Acute lymphocytic leukemia -- Drug therapy -- Genetic aspects, Cancer -- Genetic aspects, Universities and colleges -- Florida, Health
Abstract

Data detailed in 'Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia' have been presented. 'T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic neoplasm characterized by malignant expansion of immature [...]

Published
2011

37. Investigations show that telomerase inhibitor PinX1 is a key tumor suppressor

Subjects
Tumors -- Drug therapy -- Genetic aspects, Carrier proteins -- Investigations -- Genetic aspects, Cancer -- Genetic aspects -- Care and treatment -- Drug therapy, Telomerase -- Investigations -- Genetic aspects, DNA polymerases -- Genetic aspects -- Investigations, Company legal issue, Biotechnology industry, Pharmaceuticals and cosmetics industries, Beth Israel Deaconess Medical Center -- Investigations
Abstract

BOSTON - It's been nearly 10 years since Beth Israel Deaconess Medical Center (BIDMC) scientists Kun Ping Lu, MD, PhD and Xiao Zhen Zhou, MD, discovered PinX1, the first potent [...]

Published
2011

38. Trial of new treatment for advanced melanoma shows rapid shrinking of tumors

Subjects
Oncology, Experimental -- Drug therapy -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Cancer -- Care and treatment -- Research, Clinical trials -- Genetic aspects, Melanoma -- Drug therapy -- Genetic aspects
Abstract

Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according [...]

Published
2009

39. Hematopoietic tumor treatment should involve developing therapies that target HAUSP

Subjects
Tumors -- Drug therapy -- Genetic aspects, Tumor proteins -- Drug therapy -- Genetic aspects, Ubiquitin, Cancer -- Care and treatment, Health, Science and technology, Drug therapy, Genetic aspects
Abstract

Developing therapies that target HAUSP could be used to treat hematopoietic tumors. According to recent research from South Korea, "P53, one of the most important tumor suppressor proteins, plays an [...]

Published
2006

40. Hematopoietic tumor treatment should involve developing therapies that target HAUSP

Subjects
Tumors -- Drug therapy -- Genetic aspects, Tumor proteins -- Drug therapy -- Genetic aspects, Ubiquitin, Cancer -- Care and treatment, Health, Drug therapy, Genetic aspects
Abstract

Developing therapies that target HAUSP could be used to treat hematopoietic tumors. According to recent research from South Korea, "P53, one of the most important tumor suppressor proteins, plays an [...]

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results